Fusion AntibodiesLSE:FAB 33 Days Inventory is 83.53 as of Sep. 2025, which is 19% above its 10-year median of 69.90. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 635 Biotechnology companies, Fusion Antibodies ranks better than 79.53% on this metric.
The historical rank and industry rank for Fusion Antibodies's Days Inventory or its related term are showing as below:
LSE:FAB'
s Days Inventory Range Over the Past 10 Years
Min: 22.96 Med: 69.9 Max: 154.38
Current: 75.41
During the past 11 years, Fusion Antibodies's highest Days Inventory was 154.38. The lowest was 22.96. And the median was 69.90.
LSE:FAB's Days Inventory is ranked better than 79.53% of 635
companies
in the Biotechnology industry
Industry Median: 183.23
vs LSE:FAB: 75.41
Fusion Antibodies's Days Inventory
increased
from Sep. 2024 (71.39) to Sep. 2025 (83.53).
It might indicate that Fusion Antibodies's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Fusion Antibodies's Inventory Turnover for the
six
months ended in Sep. 2025 was 2.18.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fusion Antibodies's Inventory-to-Revenue for the
six
months ended in Sep. 2025 was 0.32.
Fusion Antibodies (LSE:FAB) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Fusion Antibodies's Inventory Turnover for the
six
months ended in Sep. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fusion Antibodies's Inventory to Revenue for the
six
months ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Fusion Antibodies Days Inventory Related Terms
Fusion Antibodies Days Inventory Historical Data
* Premium members only.
The historical data trend for Fusion Antibodies's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Fusion Antibodies's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's Days Inventory distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a Days Inventory of 83.53 as of Sep. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fusion Antibodies and its competitors. This is 19% above median its historical median of 69.90. Over the past decade, Fusion Antibodies' Days Inventory has ranged from 22.96 to 154.38. According to the industry distribution chart, Fusion Antibodies ranks #130 out of 635 companies in the Biotechnology industry, placing it in the top 20.5%.
Is Fusion Antibodies' Days Inventory too high?
Fusion Antibodies' current Days Inventory of 83.53 is 19% above median its 10-year median of 69.90. Over the past 10 years, this metric has ranged from a low of 22.96 to a high of 154.38. The Biotechnology industry median Days Inventory is 183.23. Fusion Antibodies' value of 83.53 is 54.4% below this industry median. Based on the distribution chart, Fusion Antibodies ranks #130 out of 635 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #130 out of 635 companies for Days Inventory. This places Fusion Antibodies in the top 21% of its industry — outperforming the majority of peers. The industry median Days Inventory is 183.23. Fusion Antibodies' value of 83.53 is 54.4% below this benchmark. Historically, Fusion Antibodies' own Days Inventory has ranged from 22.96 to 154.38 over the past decade. While the company's 10-year median is 69.90 vs. the industry median of 183.23, Fusion Antibodies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.23, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fusion Antibodies's current Days Inventory of 83.53 is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fusion Antibodies and its competitors. For the Biotechnology industry, the median Days Inventory is 183.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current Days Inventory is 83.53, which is 19% above median its own 10-year median of 69.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 200% above its estimated fair value. The current Days Inventory is 83.53, which is 19% above median its 10-year median of 69.90 and 54.4% below the Biotechnology industry median of 183.23. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Days Inventory is 83.53 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.12 is trading 200% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
Days Inventory: 83.53 (19% above median its 10-year median of 69.90)
GF Value™: £0.04 vs. price of £0.12 (200% above fair value)
Industry Position: 54.4% below the Biotechnology median (#130 of 635)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score
Get the complete analysis for LSE:FAB
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
